CRO Insights that drive clinical research forward

Expertise, Scale, and Trust in First-in-Human and Early Development At Aixial, we believe early phase trials—especially first-in-human (FIH) studies—set the…

Sarcomas are a diverse and rare group of malignant tumors arising from mesenchymal tissues, including bone, muscle, fat, and connective tissue.

Brain tumours remain one of the most formidable challenges in medical science due to their complex biology, high morbidity, and limited treatment options.

Q&A with Aixial’s experts at ASCO 2025. Learn how we can drive success in complex oncology trials. Find us at Booth #27150.

Ovarian cancer is one of the most lethal gynecologic malignancies worldwide, often diagnosed at an advanced stage due to subtle or non-specific symptoms.

Monoclonal antibodies (mAbs) have revolutionized the landscape of neurodegenerative disease research…

On April 11, World Parkinson’s Day, we are reminded of the importance of research in improving treatments and finding a cure.

In the European Union, a rare disease is defined as one affecting fewer than 5 out of 10,000 members of the general population…

The field of CGT is revolutionizing modern medicine, offering potential curative treatments for diseases previously considered untreatable…

Honor women’s significant achievements in science and place a much-needed focus on girls entering Science, Technology, Engineering, and Mathematics (STEM) careers.

Ashley Hunter and Anna Yanaeva led an engaging discussion on the importance of “Utilising CROs for Effective Planning and Execution of Clinical Development”.

Clear communication is essential to drug development. At Aixial Group, our experienced medical writers know how to turn complex scientific data into clear, accurate documents.

Pancreatic cancer is the 12th most common cancer in the world and remains one of the deadliest, with a five-year survival rate of only 13%, despite recent progress.

Breakthrough — Radiopharmaceutical therapy represents a novel approach to treating cancer, utilising radioactive atoms to target and destroy malignant cells with precision, without affecting the patient’s healthy tissues.

Did you know that lung cancer is the most diagnosed cancer in the world? In 2022, it accounted for 12.4% of all new cancer cases and 18.7% of deaths.

Prostate cancer is on the increase globally, especially in men under the age of 50, and in 2022 there were 1.47 million new cases.

In recognition of Breast Cancer Awareness Month, Ashley Hunter, Head of Strategic Development and Delivery…

One of the biggest challenges for researchers today is the threat of a conflict of interest in clinical trials (COI).

Clinical trials are designed to make sure that new treatments are better than existing ones. To do this, trials are structured by a framework that is made up of phases.

Decentralised clinical trials are a type of trial design used by studies to collect data from their participants. How data is collected can impact the trial’s efficiency, accuracy, and overall success and outcome.

Insights from Matilde Thye Kveiborg, Director of Medical Writing and Tanja Jensen, Senior Medical Writer

Rare diseases are often multifaceted, and a single endpoint is often not sufficient to fully describe treatment

Radiopharmaceutical therapy utilizes radioactive atoms to target and precisely treat cancer cells.

At the bottom of the EBM hierarchy, mechanistic evidence is not highly valued by the HTA bodies responsible for…

Lionel RIOU FRANÇA, Chief Scientific Officer, was involved in two analyses involving patients with Late-Onset Pompe…

Cell and gene therapies are multiplying, and with them the hopes of patients, their families, and healthcare professionals…

Conducting a Phase I First-In-Human (FIH) trial for Wilson’s Disease presents unique challenges due to the rarity…

Cell & Gene Therapy: Safety and Clinical Activity in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma Case…

Aixial Group is currently collaborating with a US pharmaceutical company on a Phase II clinical trial involving paediatric patients with specific inherited metabolic disorders…

Data Science & Analytics: Combining A Phase I Study with an On-Going Observational Study Case study This case study looks…

Early Phase Oncology: First-In-Human Study Of An Antibody-Drug Conjugate In Breast Cancer Case study For a First In Human study,…

Early-Phase Oncology: First-In-Human Study in Advanced Solid Tumors Case study Read more For a First In Human study, site activation…

Conducting research in rare diseases like Primary Biliary Cholangitis (PBC) presents unique challenges due to limited precedents and small patient population.

Efficient Publication Strategy Leads to Expedited Submission and Acceptance Case study Since the World Health Organization (WHO) launched the Global…

Navigating the latest ICH E8(R1) Guideline Revisions Read more Becoming fully compliant with the latest and soon-to-be released ICH E8(R1)…

Since ICH-GCP E6 R2 made Risk-Based Quality Management (RBQM) ‘official’ back in 2017, we’ve seen an increased uptake…

Aixial FSP models: Expand your data management and biostatistics capabilities Whatever your existing study team structure and study data output…

Data Science & Analytics Data science and analytics solutions to fit your needs perfectly. Enhance the power of your trials…

Our experience in First-In-Human and Early Phase Oncology Trials Overview of Aixial Group’s in-depth experience in the areas of First-In-…

Top 10 Things to Look for in a Specialist Data & Analytics CRO Partner This helpful resource takes the guess…

Expert Medical Writing For Your Every Need Our medical writing experts can help you tailor a complete range of regulatory…

Commitment to Patient Centricity and Diversity: Key ingredients for a successful trial November marks the start of Movember, an annual…

Omicron Presents New Challenges for Early Phase Trials The evolving coronavirus disease 2019 (COVID-19) pandemic continues to present challenges for…

How to report clinical trials affected by the COVID-19 pandemic: Dealing with extraordinary circumstances Since 2020, the COVID-19 pandemic has…

Flexibility and Speed In Early Phase Clinical Trials Written by Crista Casey, Executive VP Global Head of Operations First and…

How to Cut the Negative Impact of Protocol Amendments May 8, 2023 Social distancing laws in response to the COVID-19…

At Aixial Group, we deployed some immediate response measures like providing our holistic platform not for profit for COVID-19 trials and our ongoing business…

Recipe for Success in Radiopharmaceutical Studies Read more Written by Sue Batchelor, Senior Director, Clinical Operations and Delivery Radiopharmaceutical studies…

Right now, a global movement to eliminate cervical cancer is being driven by the energy, passion and momentum…

Biotechnology’s Trusted Partner from Start to Finish Read more Aixial Group’s team of clinical experts can support your biotechnology company…